Efficacy of Aksaritmin in premature ventricular contractions

32^nd International Conference on Cardiology and Healthcare

March 25, 2022 | Webinar

Husniddin Kuchkarov

Republican specialized scientific and practical medical center of cardiology, Tashkent, Uzbekistan

Scientific Tracks Abstracts: Card Dis Diag

Abstract :

Background: Aksaritmin (an active ingredient is lappaconitini hydrobromidum) is an antiarrhythmic drug (conditionally belongs to the I C class) which is extracted from the roots and rhizomes of local plant - Aconitum septentrionale (tablet 25 mg). Purpose: Evaluation of effectiveness of local plant antiarrhythmic drug (AAD) Aksaritmin in patients with premature ventricular contractions (PVC). Materials and methods: The study included 50 patients (27 men), mean age - 53.9±11.8 y.o. with premature ventricular contractions (PVC). Criteria for inclusion in the study: symptomatic PVC II-IVb gradations according to Lown-Wolf. Criteria for exclusion in the study: structural heart disease. All patients underwent a study of the necessary biochemical blood parameters, electrocardiography, 24-hour ECG monitoring, transthoracic echocardiography. According to the study protocol, the starting dose of aksaritmin was 75 mg per day, with a possible dose increase to 112.5 mg per day. The antiarrhythmic efficacy (AAE) of the drugs was assessed on the 5-7th days of taking, as well as after 1, 6 and 12 months from the start of taking. In cases of decreasing a number of PVCs by 70% or more, it was considered as positive AAE. Statistical analysis of the results was carried out by STATISTICA 13. Differences were considered statistically significant at p<0.05. Results: Analysis of the AAE of the drug performed on 5-7th days showed that at a dose of 75 mg/day, aksaritmin had AAE in 41 (82%) of 50 patients. The total effect (100% reduction of PVC) of aksaritmin at a dose of 75-112.5 mg/day was 88%. In the dynamics of 1-month 37 (74%) patients had a positive AAE (χ2 = 0.932; p>0.05). At the next stage (6 months), positive AAE was observed (maintained) in 35 (70%) patients (χ2 = 1.974; p>0.05). At the end of the year, positive AAE was noted in 34 (68%) cases (χ2 = 2.613; p>0.05). The daily number of PVC before taking aksaritmin was 5122.28±6005.22/day, after 1 week from the start of taking the drug 767.32±1286.17/day; after 1st month - 1117.94±2117.33/day, at 6 months 566.4±1252.57/day and at 12 months 600.2±1017.13/day. Conclusions: 1.With a course of taking aksaritmin at a dose of 75-112.5 mg/day, it has a positive AAE (>50%) in 82% of patients with PVC, which is considered to be a good result. 2.With long-term use of aksaritmin, decreasing of AAE (from 82% to 68%) was not statistically significant (χ2 = 2.613; p>0.05) and was mainly associated with an exacerbation of the underlying disease.

Biography :

Husniddin Kuchkarov. has completed her medical school and Republican specialized scientific and practical medical center of cardiology, Tashkent, Uzbekistan.